The discovery may explain why cutting edge CAR T-cell therapy has managed to revolutionized treatment for blood cancer but ...

New research has found a novel target with therapeutic potential for metastatic eye melanoma—an aggressive eye cancer—with ...

Biomodal reports methylation sequencing is expanding the window for early detection.

J&J is looking to add a hormone-sensitive indication to its prostate cancer therapy, which was originally approved in 2023.

A University of Alberta research team has identified a DNA structure that activates the immune system in cancer cells that ...

The FDA approves a rapid test for identifying patients with NSCLC eligible for sunvozertinib, enhancing timely, precision ...

J&J has rights to niraparib in prostate cancer, and views the drug as a successor to Zytiga, once a $2.5 billion-a-year ...

Molecular profiling could reduce both overtreatment and undertreatment of patients with high-intermediate risk endometrial ...

Investigating how mutations in tumors alter DNA’s 3D structure—and subsequently, regulatory sequences called enhancers—can ...

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced data from a colorectal ...

In a multi-institutional study published in Science Direct, researchers revealed that testing urine-based tumor DNA (utDNA) ...